1.Peb muab
(1) Tablet
(2) Cov
(3) Capsule
(4) Txau
(5) API (Ntshiab hmoov)
(6) Pill press machine
https://www.achievechem.com/pill-xwm
2.Customization:
Peb yuav sib tham tus kheej, OEM / ODM, Tsis muaj hom, rau kev tshawb nrhiav kev ruaj ntseg nkaus xwb.
Tus Qauv Zauv: BM-6-019
Semaglutide CAS 910463-68-2
Kev tshuaj xyuas: HPLC, LC-MS, HNMR
Kev them nyiaj yug Technology: R&D Dept.-4
Peb muab semaglutide capsule, thov xa mus rau lub vev xaib hauv qab no kom paub meej cov lus qhia thiab cov ntaub ntawv khoom.
Khoom siv:https://www.bloomtechz.com/oem-odm/capsule-softgel/semaglutide-capsule.html
Novo Nordisk's "Ecoinsulin Simaglutide Compound" tau pom zoo rau kev ua lag luam hauv Suav teb
Thaum Lub Peb Hlis 6, 2026, raws li lub vev xaib raug cai ntawm Lub Xeev Food and Drug Administration, Novo Nordisk's Icosamesiglutide txhaj (lcoSema) tau pom zoo rau kev lag luam los kho mob ntshav qab zib hom 2. Ecoinsulin semaglutide txhaj yog ib qho tshuaj sib xyaw tsim los ntawm Novo Nordisk, muaj ob yam khoom xyaw nquag, icodec insulin thiab semaglutide. Yike insulin yog lub sijhawm ntev heev - ua yeeb yam tshuaj insulin nrog ib nrab - lub neej txog li 196 teev hauv tib neeg lub cev. Nws tau pom zoo rau kev ua lag luam los ntawm National Medical Products Administration thaum Lub Rau Hli 2024. Simeglutide yog ib qho ntev - ua GLP-1 receptor (GLP-1 R) agonist nrog ib nrab-lub neej txog li 165 teev hauv tib neeg lub cev. Nws tau pom zoo rau kev lag luam los ntawm National Medical Products Administration thaum Lub Rau Hli 2024.
Novo Nordisk tau lees paub cov nyhuv hypoglycemic ntawm lcoSema hauv peb qhov kev tshawb fawb soj ntsuam, suav nrog Combine 1, Combine 2, thiab Combine 3.
Hansen Pharmaceuticals GLP-1R / GIPR agonist theem kuv ua tiav kev kho mob
Thaum Lub Peb Hlis 7, 2026, Hansen Pharmaceutical Group Co., Ltd. ("Hansen Pharmaceutical", 03692. HK) tshaj tawm tias nws thawj cov tshuaj poob phaus - glucagon zoo li peptide-1 receptor (GLP-1R)/glucose dependent} insulin zoo li polyGIpeptide{13} olecitol (HS{14}}20094) - ua tiav nws cov ntsiab lus kawg hauv thawj theem kev kho mob (HS-20094-301) ua rau cov neeg laus rog rog lossis rog rog hauv Suav teb. Qhov kev tshawb fawb no tau ua tiav, ob qhov muag tsis pom kev, kev tswj cov placebo tau ua nyob rau hauv 33 lub chaw kho mob hauv Suav teb, nrog rau tag nrho 604 tus neeg laus kawm. Lub hom phiaj yog los ntsuas qhov ua tau zoo thiab kev nyab xeeb ntawm ib lub lis piam ib zaug omeprazole piv rau kev kho cov placebo rau 48 lub lis piam. Txoj kev tshawb no tau ua tiav qhov tseem ceeb ntawm qhov kawg:
At 48 weeks of treatment, there was a statistically significant difference in the decrease in body weight compared to baseline in the olepotide group and the placebo group, with a significantly higher proportion of subjects achieving a 5% weight reduction in the olepotide group. After 48 weeks of treatment with olepotide, the average decrease in body weight from baseline was as high as 19.3%, and the proportion of subjects who achieved a weight gain of>5% yog siab txog 97.2%. Cov kev tshawb fawb tau pom tias pab pawg kho mob olepotide tau pom zoo rau kev mob plab hnyuv siab raum, nrog qis qis ntawm cov kab mob plab hnyuv thiab cov kev kho mob tsis tu ncua piv rau cov ntaub ntawv txuas ntxiv ntawm GLP-1 ntsig txog ob tus agonists uas tau luam tawm.
Sihe Gene ASO Therapy SG12 Txhaj Pom Zoo rau Kev Siv Tshuaj Kho Mob
Thaum Lub Peb Hlis 9, 2026, Sihegen (Beijing) Biotechnology Co., Ltd. (hu ua "Sihegen") tau tshaj tawm tias nws tau tsim nws tus kheej tsim cov tshuaj tshiab 1 antisense oligonucleotide (ASO) rau kev kho mob ntawm tus kab mob siab B, SG12 Txhaj Tshuaj (xa mus rau), uas tau pom zoo los ntawm Kev Tswj Xyuas Kev Kho Mob SG2. (IND). Pom zoo cov txheej txheem kho mob: Kev nyab xeeb thiab kev ua siab ntev, cov yam ntxwv ntawm cov tshuaj pharmacokinetic, thiab kev ua haujlwm ua ntej ntawm ntau cov koob tshuaj, ib zaug thiab ntau qhov kev txhaj tshuaj subcutaneous ntawm SG12 hauv cov neeg laus noj qab haus huv thiab HBeAg cov neeg mob tsis zoo rau kab mob siab B tau kho nrog nucleoside analogues! Phase II kev sim tshuaj.
Lub tswv yim ntawm kev ua yog tias ASO cov tshuaj tsim los ntxiv rau qhov tseem ceeb ntawm mRNA ib ntus ntawm tus kab mob siab B tuaj yeem cuam tshuam cov synthesis ntawm cov kab mob ntsig txog cov proteins (xws li kab mob siab B nto antigen HBSAg). Txo lossis txawm tias tshem tawm HBsAg yog suav tias yog kauj ruam tseem ceeb hauv kev rov pib tus neeg mob cov lus teb autoimmune thiab ua tiav kev kho mob.
Cov txiaj ntsig zoo tau ua tiav nyob rau theem kuv kawm ntawm AbbVie ntev - ua yeeb yam amylin analogs
Thaum Lub Peb Hlis 9, 2026, AbbVie tau tshaj tawm cov txiaj ntsig zoo hauv Phase I dose escalation (MAD) txoj kev kawm ntawm ABBV-295. ABBV-295 yog qhov ua haujlwm ntev peptide analogue ntawm amyloid qhia los ntawm AbbVie los ntawm Gubra, uas tuaj yeem qhib cov amyloid receptor (AMYR) thiab calcitonin receptor (CalcR). Txoj kev tshawb no tau soj ntsuam kev nyab xeeb, kev ua siab ntev, pharmacokinetics (PK), thiab pharmacodynamics (PD) ntawm ntau yam kev txhaj tshuaj subcutaneous ntawm ABBV-295 (2-14mg) hauv cov neeg laus uas muaj qhov nruab nrab BMI tsawg dua 30kg / m2.
Cov txiaj ntsig tau pom tias thaum lub sijhawm 12-13 lub lis piam kev kho mob, qhov poob phaus ntawm cov neeg mob hauv txhua pawg koob tshuaj ABBV-295 muaj qhov tseem ceeb hauv kev kho mob thiab yog nyob ntawm koob tshuaj,. Tsis tas li ntawd, ABBV-295 tau nthuav tawm cov txiaj ntsig zoo ntawm txhua qib. Feem ntau tshaj tawm cov xwm txheej tsis zoo yog qhov tshwm sim hauv plab hnyuv, feem ntau yog mob me thiab feem ntau tshwm sim hauv thawj 6 lub lis piam ntawm kev kho mob. Tsis muaj qhov tshwm sim tsis zoo (SAEs) tau tshaj tawm.
